Dimerix

Dimerix FCF/Net Income

The Free Cash Flow to Net Income Ratio of Dimerix (DXB.AX) as of Oct 22, 2026 is 173.80 %. In the previous year, Free Cash Flow to Net Income Ratio was -294.54 % — a change of -159.01% (higher).

FCF/Net Income

173.80 %

YoY

-159.01%

Last updated:

Free Cash Flow to Net Income Ratio of Dimerix is 2026 173.80 % . Free Cash Flow to Net Income Ratio of Dimerix was 2025 -294.54 % . It decreases by -159.01% higher compared to the previous year.

The Dimerix FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2019
95.55 AUD
Jan 1, 2020
105.27 AUD
Jan 1, 2021
101.57 AUD
Jan 1, 2022
128.17 AUD
Jan 1, 2023
92.25 AUD
Jan 1, 2024
41.11 AUD
Jan 1, 2025
-294.54 AUD
Jan 1, 2026
173.80 AUD
The Dimerix FCF/Net Income history
YEARFCF/Net IncomeYoY
173.80 %-159.01%
-294.54 %-816.44%
41.11 %-55.43%
92.25 %-28.03%
128.17 %+26.19%
101.57 %-3.51%
105.27 %+10.17%
95.55 %-1.75%
97.26 %-8.37%
106.14 %+303.77%
26.29 %-68.33%
83.00 %-68.12%
260.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Free Cash Flow to Net Income Ratio of Dimerix is 173.80 % in 2026.

Free Cash Flow to Net Income Ratio of Dimerix changed from -294.54 % to 173.80 %, representing a -159.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio Dimerix since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's Dimerix with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Dimerix

All Key Metrics — Dimerix